Liver function tests in identifying patients with liver disease
Received 21 December 2017
Accepted for publication 28 April 2018
Published 23 August 2018 Volume 2018:11 Pages 301—307
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Wing-Kin Syn
Zohair Ahmed,1 Umair Ahmed,2 Saqib Walayat,2 Jinma Ren,3 Daniel K Martin,4 Harsha Moole,2 Sean Koppe,5 Sherri Yong,6 Sonu Dhillon4
1Department of Gastroenterology and Hepatology, University of Illinois, Chicago, IL, USA; 2Department of Internal Medicine, University of Illinois College of Medicine, Peoria, IL, USA; 3Department of Center for Outcomes Research, University of Illinois College of Medicine, Peoria, IL, USA; 4Department of Gastroenterology and Hepatology, University of Illinois College of Medicine, Peoria, IL, USA; 5Department of Hepatology, University of Illinois at Chicago, Chicago, IL, USA; 6Department of Pathology, University of Illinois College of Medicine, Peoria, IL, USA
Background and aims: Many patients with liver disease come to medical attention once they have advanced cirrhosis or acute decompensation. Most often, patients are screened for liver disease via liver function tests (LFTs). There is very limited published data evaluating laboratory values with biopsy-proven stages of hepatic fibrosis. We set out to evaluate whether any correlation exists between routine LFTs and stages of hepatic fibrosis.
Methods: A large retrospective observational study on 771 liver biopsies was conducted for evaluating the stage of fibrosis with AST, ALT, INR, BUN, creatinine, platelets, alkaline phosphatase, bilirubin, and albumin. Mean and 95% confidence intervals were used to describe the distributions of serum markers in different fibrosis stages. Multivariable generalized linear models were used and a two-tailed P-value was calculated.
Results: ALT was not statistically significant for any stage, and AST was statistically significant for stage 3 and 4 fibrosis. INR was statistically significant only in stage 4 disease but remained near the upper limit of normal range. Albumin failed to show a clinically relevant association. Platelets remained within normal laboratory range for all stages. The remaining laboratory values failed to show statistical and clinical significance.
Conclusion: The health care burden from chronic liver disease (CLD) will likely continue to rise, unless clinicians are made aware that normal or near normal laboratory findings may be seen in asymptomatic patients. Earlier identification of asymptomatic patients will allow for treatment with new promising modalities and decrease morbidity and mortality from CLD. Our study shows that laboratory values correlate poorly with liver disease.
Keywords: chronic liver disease, hepatic fibrosis, serum markers, cirrhosis, NAFLD, HCV
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]